On the public citation graph

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

https://doi.org/10.1073/pnas.1203201109

0 signed · 327 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/0092-8674(82)90065-4openalex-snapshot

Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas

inferredcites →https://doi.org/10.1016/0092-8674(86)90779-8openalex-snapshot

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185

inferredcites →https://doi.org/10.1016/j.bcp.2010.03.001openalex-snapshot

Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”

inferredcites →https://doi.org/10.1016/j.ccr.2006.05.023openalex-snapshot

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

inferredcites →https://doi.org/10.1016/j.cell.2011.02.003openalex-snapshot

Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase

inferredcites →https://doi.org/10.1016/j.molmed.2011.01.012openalex-snapshot

Targeting mutant fibroblast growth factor receptors in cancer

inferredcites →https://doi.org/10.1038/339230a0openalex-snapshot

A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

inferredcites →https://doi.org/10.1038/431525bopenalex-snapshot

Intragenic ERBB2 kinase mutations in tumours

inferredcites →https://doi.org/10.1038/nature01392openalex-snapshot

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

inferredcites →https://doi.org/10.1038/nature07385openalex-snapshot

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

inferredcites →https://doi.org/10.1038/nature07423openalex-snapshot

Somatic mutations affect key pathways in lung adenocarcinoma

inferredcites →https://doi.org/10.1038/nature09004openalex-snapshot

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

inferredcites →https://doi.org/10.1038/nature09208openalex-snapshot

Diverse somatic mutation patterns and pathway alterations in human cancers

inferredcites →https://doi.org/10.1038/nature10933openalex-snapshot

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

inferredcites →https://doi.org/10.1038/nature11003openalex-snapshot

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

inferredcites →https://doi.org/10.1038/nature11154openalex-snapshot

Sequence analysis of mutations and translocations across breast cancer subtypes

inferredcites →https://doi.org/10.1038/ng.363openalex-snapshot

Human mutation rate associated with DNA replication timing

inferredcites →https://doi.org/10.1038/nm.2645openalex-snapshot

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

inferredcites →https://doi.org/10.1038/nprot.2006.427openalex-snapshot

A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)

inferredcites →https://doi.org/10.1038/onc.2008.109openalex-snapshot

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

inferredcites →https://doi.org/10.1038/sj.onc.1203396openalex-snapshot

The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells

inferredcites →https://doi.org/10.1038/sj.onc.1210292openalex-snapshot

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272

inferredcites →https://doi.org/10.1056/nejm200104053441402openalex-snapshot

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

inferredcites →https://doi.org/10.1056/nejmoa040938openalex-snapshot

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

inferredcites →https://doi.org/10.1056/nejmoa064320openalex-snapshot

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

inferredcites →https://doi.org/10.1056/nejmoa0810699openalex-snapshot

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

inferredcites →https://doi.org/10.1056/nejmoa1006448openalex-snapshot

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1073/pnas.0405220101openalex-snapshot

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

inferredcites →https://doi.org/10.1073/pnas.0803379105openalex-snapshot

Drug-sensitive FGFR2 mutations in endometrial carcinoma

inferredcites →https://doi.org/10.1073/pnas.93.17.8878openalex-snapshot

Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.

inferredcites →https://doi.org/10.1101/gr.098947.109openalex-snapshot

Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes

inferredcites →https://doi.org/10.1126/science.1073096openalex-snapshot

Addiction to Oncogenes--the Achilles Heal of Cancer

inferredcites →https://doi.org/10.1126/science.1099314openalex-snapshot

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

inferredcites →https://doi.org/10.1126/science.1164382openalex-snapshot

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

inferredcites →https://doi.org/10.1126/science.2885917openalex-snapshot

erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

inferredcites →https://doi.org/10.1126/science.3798106openalex-snapshot

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

inferredcites →https://doi.org/10.1128/mcb.14.11.7068openalex-snapshot

Novel Activating Mutations in the neu Proto-oncogene Involved in Induction of Mammary Tumors

inferredcites →https://doi.org/10.1128/mcb.20.20.7735-7750.2000openalex-snapshot

Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain

inferredcites →https://doi.org/10.1128/mcb.20.5.1526-1536.2000openalex-snapshot

Molecular Mechanism for the Shp-2 Tyrosine Phosphatase Function in Promoting Growth Factor Stimulation of Erk Activity

inferredcites →https://doi.org/10.1158/0008-5472.can-04-4235openalex-snapshot

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

inferredcites →https://doi.org/10.1158/0008-5472.can-06-0971openalex-snapshot

Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272

inferredcites →https://doi.org/10.1172/jci39703openalex-snapshot

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

inferredcites →https://doi.org/10.1177/1947601911407324openalex-snapshot

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies

inferredcites →https://doi.org/10.1182/blood.v97.3.729openalex-snapshot

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

inferredcites →https://doi.org/10.17615/hvp3-wg08openalex-snapshot

Integrated genomic analyses of ovarian carcinoma

inferredcites →https://doi.org/10.3322/caac.20121openalex-snapshot

Cancer statistics, 2011

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4155240openalex-extracted

HER2-Activating Missense Mutations in Advanced Non-Small Cell Lung Cancer: Rare But Targetable Spot Should Not Be Neglected

inferred← citeshttps://doi.org/10.1001/jamaoncol.2015.2286openalex-snapshot

The Evolving Landscape of HER2 Targeting in Breast Cancer

inferred← citeshttps://doi.org/10.1001/jamaoncol.2016.2719openalex-snapshot

The Role of Genetic Testing in the Selection of Therapy for Breast Cancer

inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.0775openalex-snapshot

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma

inferred← citeshttps://doi.org/10.1002/1878-0261.70189openalex-snapshot

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

inferred← citeshttps://doi.org/10.1002/9781118468791.ch4openalex-snapshot

Somatic Genome Alterations in Human Lung Cancers

inferred← citeshttps://doi.org/10.1002/9781118674826.ch29openalex-snapshot

Molecular events in muscle‐invasive bladder cancer development

inferred← citeshttps://doi.org/10.1002/ange.201307387openalex-snapshot

Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor

inferred← citeshttps://doi.org/10.1002/anie.201307387openalex-snapshot

Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor

inferred← citeshttps://doi.org/10.1002/cam4.432openalex-snapshot

HER2 as a target in invasive urothelial carcinoma

inferred← citeshttps://doi.org/10.1002/cam4.6441openalex-snapshot

Immune checkpoint inhibitor‐related molecular markers predict prognosis in extrahepatic cholangiocarcinoma

inferred← citeshttps://doi.org/10.1002/cam4.6680openalex-snapshot

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD ‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

inferred← citeshttps://doi.org/10.1002/cncr.29826openalex-snapshot

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

inferred← citeshttps://doi.org/10.1002/cncr.30102openalex-snapshot

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

inferred← citeshttps://doi.org/10.1002/cncr.30254openalex-snapshot

Biliary cancer: Utility of next‐generation sequencing for clinical management

inferred← citeshttps://doi.org/10.1002/cncr.31125openalex-snapshot

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3

inferred← citeshttps://doi.org/10.1002/cncy.21338openalex-snapshot

Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms

inferred← citeshttps://doi.org/10.1002/ctm2.254openalex-snapshot

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies

inferred← citeshttps://doi.org/10.1002/gcc.22442openalex-snapshot

Comparable clinical outcomes in patients with HER2‐mutant and EGFR‐mutant lung adenocarcinomas

inferred← citeshttps://doi.org/10.1002/ijc.32138openalex-snapshot

LIPG‐promoted lipid storage mediates adaptation to oxidative stress in breast cancer

inferred← citeshttps://doi.org/10.1002/iub.2060openalex-snapshot

More than the sum of the parts: Toward full‐length receptor tyrosine kinase structures

inferred← citeshttps://doi.org/10.1002/mgg3.201openalex-snapshot

Capture‐based next‐generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing

inferred← citeshttps://doi.org/10.1007/978-1-4939-0727-4_24openalex-snapshot

Genomic Applications in Pulmonary Malignancies

inferred← citeshttps://doi.org/10.1007/978-1-4939-7154-1_12openalex-snapshot

Identification and Validation of Driver Kinases from Next-Generation Sequencing Data

inferred← citeshttps://doi.org/10.1007/978-3-030-17832-1_6openalex-snapshot

Targeting HER2 in Lung Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-48848-6_16openalex-snapshot

The Pathology Report

inferred← citeshttps://doi.org/10.1007/978-94-007-7975-4_3openalex-snapshot

Identifying Driver Mutations in Cancer

inferred← citeshttps://doi.org/10.1007/s00210-014-0967-3openalex-snapshot

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

inferred← citeshttps://doi.org/10.1007/s00428-014-1699-yopenalex-snapshot

Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma

inferred← citeshttps://doi.org/10.1007/s00428-018-2414-1openalex-snapshot

Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer

inferred← citeshttps://doi.org/10.1007/s10549-015-3336-0openalex-snapshot

Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast

inferred← citeshttps://doi.org/10.1007/s10549-017-4176-xopenalex-snapshot

Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients

inferred← citeshttps://doi.org/10.1007/s10549-017-4419-xopenalex-snapshot

Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature

inferred← citeshttps://doi.org/10.1007/s10549-018-5049-7openalex-snapshot

Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations

inferred← citeshttps://doi.org/10.1007/s10549-020-05763-7openalex-snapshot

Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer

inferred← citeshttps://doi.org/10.1007/s10555-026-10353-yopenalex-snapshot

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward

inferred← citeshttps://doi.org/10.1007/s11912-015-0477-6openalex-snapshot

Targeting Signaling Transduction Pathways in Bladder Cancer

inferred← citeshttps://doi.org/10.1007/s12032-021-01568-wopenalex-snapshot

ERBB2 S310F mutation independently activates PI3K/AKT and MAPK pathways through homodimers to contribute gallbladder carcinoma growth

inferred← citeshttps://doi.org/10.1007/s12282-015-0659-yopenalex-snapshot

HER2 mutation status in Japanese HER2-positive breast cancer patients

inferred← citeshttps://doi.org/10.1007/s12609-018-0265-zopenalex-snapshot

HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer

inferred← citeshttps://doi.org/10.1007/s12672-024-01154-2openalex-snapshot

Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study

inferred← citeshttps://doi.org/10.1007/s13277-015-4768-1openalex-snapshot

Inhibition of proliferation and induction of apoptosis in RB116 retinoblastoma cells by afatinib treatment

inferred← citeshttps://doi.org/10.1007/s13402-021-00656-3openalex-snapshot

Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test

inferred← citeshttps://doi.org/10.1007/s40291-013-0070-3openalex-snapshot

Comprehensive Profiling of EGFR/HER Receptors for Personalized Treatment of Gynecologic Cancers

inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00002-5openalex-snapshot

Intracellular Signaling

inferred← citeshttps://doi.org/10.1016/j.ajpath.2017.04.021openalex-snapshot

The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics

inferred← citeshttps://doi.org/10.1016/j.ajpath.2019.10.004openalex-snapshot

Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder

inferred← citeshttps://doi.org/10.1016/j.bmcl.2013.11.064openalex-snapshot

Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer

inferred← citeshttps://doi.org/10.1016/j.bpj.2014.11.3460openalex-snapshot

Effect of Thanatophoric Dysplasia Type I Mutations on FGFR3 Dimerization

inferred← citeshttps://doi.org/10.1016/j.canlet.2018.07.014openalex-snapshot

Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect

inferred← citeshttps://doi.org/10.1016/j.ccell.2015.12.012openalex-snapshot

Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma

inferred← citeshttps://doi.org/10.1016/j.ccell.2018.09.010openalex-snapshot

Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

inferred← citeshttps://doi.org/10.1016/j.ccell.2019.09.001openalex-snapshot

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

inferred← citeshttps://doi.org/10.1016/j.ccell.2021.06.001openalex-snapshot

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

inferred← citeshttps://doi.org/10.1016/j.cell.2026.04.010openalex-snapshot

ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging

inferred← citeshttps://doi.org/10.1016/j.celrep.2015.02.014openalex-snapshot

ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis

inferred← citeshttps://doi.org/10.1016/j.celrep.2015.03.044openalex-snapshot

Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer

inferred← citeshttps://doi.org/10.1016/j.celrep.2022.111268openalex-snapshot

ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain

inferred← citeshttps://doi.org/10.1016/j.cels.2015.08.014openalex-snapshot

Pan-Cancer Analysis of Mutation Hotspots in Protein Domains

inferred← citeshttps://doi.org/10.1016/j.clbc.2016.08.001openalex-snapshot

A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.103997openalex-snapshot

A review of HER2 overexpression and somatic mutations in cancers

inferred← citeshttps://doi.org/10.1016/j.ctrv.2014.02.007openalex-snapshot

TCTP as therapeutic target in cancers

inferred← citeshttps://doi.org/10.1016/j.ctrv.2020.101996openalex-snapshot

The force of HER2 – A druggable target in NSCLC?

inferred← citeshttps://doi.org/10.1016/j.drudis.2018.09.003openalex-snapshot

3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development

inferred← citeshttps://doi.org/10.1016/j.esmoop.2026.107772openalex-snapshot

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers

inferred← citeshttps://doi.org/10.1016/j.esmorw.2024.100036openalex-snapshot

Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data

inferred← citeshttps://doi.org/10.1016/j.eururo.2015.01.014openalex-snapshot

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

inferred← citeshttps://doi.org/10.1016/j.gore.2020.100577openalex-snapshot

An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers

inferred← citeshttps://doi.org/10.1016/j.gore.2026.102171openalex-snapshot

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against ERBB2-mutated cervical carcinomas with low HER2 expression

inferred← citeshttps://doi.org/10.1016/j.hoc.2014.10.002openalex-snapshot

Molecular Biology of Bladder Cancer

inferred← citeshttps://doi.org/10.1016/j.humpath.2019.07.006openalex-snapshot

HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features

inferred← citeshttps://doi.org/10.1016/j.jmoldx.2015.04.003openalex-snapshot

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers

inferred← citeshttps://doi.org/10.1016/j.jncc.2021.04.001openalex-snapshot

Targeting HER2 genomic alterations in non-small cell lung cancer

inferred← citeshttps://doi.org/10.1016/j.lungcan.2014.12.018openalex-snapshot

Targeting HER2 in the treatment of non-small cell lung cancer

inferred← citeshttps://doi.org/10.1016/j.lungcan.2016.05.030openalex-snapshot

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers

inferred← citeshttps://doi.org/10.1016/j.lungcan.2019.11.018openalex-snapshot

Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC

inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.02.022openalex-snapshot

Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

inferred← citeshttps://doi.org/10.1016/j.modpat.2023.100120openalex-snapshot

Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets

inferred← citeshttps://doi.org/10.1016/j.modpat.2026.101082openalex-snapshot

Primary Cutaneous Apocrine Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Characterization of 27 Cases

inferred← citeshttps://doi.org/10.1016/j.neo.2020.09.003openalex-snapshot

Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli

inferred← citeshttps://doi.org/10.1016/j.path.2020.05.007openalex-snapshot

HER2 in Colorectal Carcinoma

inferred← citeshttps://doi.org/10.1016/j.pharmthera.2019.03.010openalex-snapshot

Prevalence and role of HER2 mutations in cancer

inferred← citeshttps://doi.org/10.1016/j.premed.2026.100064openalex-snapshot

Structural modeling predicts altered disulfide connectivity in HER2 W452C

inferred← citeshttps://doi.org/10.1016/j.redox.2021.101942openalex-snapshot

Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation

inferred← citeshttps://doi.org/10.1016/j.resinv.2026.101452openalex-snapshot

Response to trastuzumab deruxtecan in postoperative recurrent lung adenocarcinoma harboring concurrent EGFR and HER2 mutations after progression on adjuvant osimertinib

inferred← citeshttps://doi.org/10.1016/j.semcancer.2017.03.007openalex-snapshot

Transcriptomic and genomic features of invasive lobular breast cancer

inferred← citeshttps://doi.org/10.1016/j.tranon.2022.101444openalex-snapshot

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

inferred← citeshttps://doi.org/10.1016/j.virol.2017.12.033openalex-snapshot

The interactome of EBV LMP1 evaluated by proximity-based BioID approach

inferred← citeshttps://doi.org/10.1016/j.ygeno.2023.110741openalex-snapshot

Deep sequencing reveals recurrent somatic mutations and distinct molecular subgroups in gastric cancer in Mizo population, North East India

inferred← citeshttps://doi.org/10.1016/j.ygyno.2020.07.025openalex-snapshot

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

inferred← citeshttps://doi.org/10.1016/j.ygyno.2023.01.015openalex-snapshot

The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo

inferred← citeshttps://doi.org/10.1016/j.ygyno.2023.12.004openalex-snapshot

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

inferred← citeshttps://doi.org/10.1017/9781009336123openalex-snapshot

Targeting Oncogenic Driver Mutations in Lung Cancer

inferred← citeshttps://doi.org/10.1021/acs.accounts.5b00238openalex-snapshot

Characterization of Membrane Protein Interactions in Plasma Membrane Derived Vesicles with Quantitative Imaging Förster Resonance Energy Transfer

inferred← citeshttps://doi.org/10.1021/acs.biochem.7b00399openalex-snapshot

Parallels and Distinctions in FGFR, VEGFR, and EGFR Mechanisms of Transmembrane Signaling

inferred← citeshttps://doi.org/10.1038/nature11903openalex-snapshot

Erratum: Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways

inferred← citeshttps://doi.org/10.1038/nature12881openalex-snapshot

Landscape of genomic alterations in cervical carcinomas

inferred← citeshttps://doi.org/10.1038/nature12965openalex-snapshot

Comprehensive molecular characterization of urothelial bladder carcinoma

inferred← citeshttps://doi.org/10.1038/nature13480openalex-snapshot

Comprehensive molecular characterization of gastric adenocarcinoma

inferred← citeshttps://doi.org/10.1038/nchembio.2171openalex-snapshot

Overcoming resistance to HER2 inhibitors through state-specific kinase binding

inferred← citeshttps://doi.org/10.1038/ncomms10131openalex-snapshot

Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas

inferred← citeshttps://doi.org/10.1038/onc.2015.185openalex-snapshot

Activating ERBB4 mutations in non-small cell lung cancer

inferred← citeshttps://doi.org/10.1038/oncsis.2016.10openalex-snapshot

The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ

inferred← citeshttps://doi.org/10.1038/s41375-020-0844-7openalex-snapshot

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

inferred← citeshttps://doi.org/10.1038/s41388-020-01404-xopenalex-snapshot

Extramammary Paget’s disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies

inferred← citeshttps://doi.org/10.1038/s41420-019-0228-9openalex-snapshot

Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway

inferred← citeshttps://doi.org/10.1038/s41467-020-17386-zopenalex-snapshot

Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival

inferred← citeshttps://doi.org/10.1038/s41467-023-36399-yopenalex-snapshot

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

inferred← citeshttps://doi.org/10.1038/s41467-024-45594-4openalex-snapshot

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants

inferred← citeshttps://doi.org/10.1038/s41467-025-67643-2openalex-snapshot

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

inferred← citeshttps://doi.org/10.1038/s41523-022-00390-5openalex-snapshot

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib

inferred← citeshttps://doi.org/10.1038/s41571-024-00924-9openalex-snapshot

HER2-targeted therapies beyond breast cancer — an update

inferred← citeshttps://doi.org/10.1038/s41586-021-04084-zopenalex-snapshot

Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface

inferred← citeshttps://doi.org/10.1038/s41588-018-0287-5openalex-snapshot

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

inferred← citeshttps://doi.org/10.1038/s41589-024-01751-wopenalex-snapshot

Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain

inferred← citeshttps://doi.org/10.1038/s41598-017-02655-7openalex-snapshot

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm

inferred← citeshttps://doi.org/10.1038/s41698-019-0090-5openalex-snapshot

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

inferred← citeshttps://doi.org/10.1038/s41698-024-00720-9openalex-snapshot

Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients

inferred← citeshttps://doi.org/10.1038/srep40488openalex-snapshot

Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing

inferred← citeshttps://doi.org/10.1039/d0bm01903hopenalex-snapshot

Single chain variable fragment fused to maltose binding protein: a modular nanocarrier platform for the targeted delivery of antitumorals

inferred← citeshttps://doi.org/10.1073/pnas.1404639111openalex-snapshot

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

inferred← citeshttps://doi.org/10.1073/pnas.1516853112openalex-snapshot

HER2 missense mutations have distinct effects on oncogenic signaling and migration

inferred← citeshttps://doi.org/10.1073/pnas.1911385116openalex-snapshot

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

inferred← citeshttps://doi.org/10.1073/pnas.2007474117openalex-snapshot

An ErbB2 splice variant lacking exon 16 drives lung carcinoma

inferred← citeshttps://doi.org/10.1073/pnas.2008017117openalex-snapshot

Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer

inferred← citeshttps://doi.org/10.1073/pnas.2413686122openalex-snapshot

Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody–drug conjugates

inferred← citeshttps://doi.org/10.1074/jbc.m114.614701openalex-snapshot

CDK1-dependent Inhibition of the E3 Ubiquitin Ligase CRL4CDT2 Ensures Robust Transition from S Phase to Mitosis

inferred← citeshttps://doi.org/10.1074/jbc.ra118.006336openalex-snapshot

An unbiased in vitro screen for activating epidermal growth factor receptor mutations

inferred← citeshttps://doi.org/10.1080/15384047.2018.1449611openalex-snapshot

Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation

inferred← citeshttps://doi.org/10.1080/15476286.2016.1267074openalex-snapshot

How is Herstatin, a tumor suppressor splice variant of the oncogeneHER2, regulated?

inferred← citeshttps://doi.org/10.1089/thy.2016.0254openalex-snapshot

Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases

inferred← citeshttps://doi.org/10.1091/mbc.e14-09-1412openalex-snapshot

Epidermal growth factor–stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis

inferred← citeshttps://doi.org/10.1093/annonc/mdv186openalex-snapshot

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

inferred← citeshttps://doi.org/10.1093/clinchem/hvaa328openalex-snapshot

Nanopore Identification of Single Nucleotide Mutations in Circulating Tumor DNA by Multiplexed Ligation

inferred← citeshttps://doi.org/10.1093/jnci/djv015openalex-snapshot

Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights

inferred← citeshttps://doi.org/10.1097/cco.0000000000000330openalex-snapshot

Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients

inferred← citeshttps://doi.org/10.1097/cco.0000000000000429openalex-snapshot

Molecular pathology of lung cancer: current status and perspectives

inferred← citeshttps://doi.org/10.1097/jto.0000000000000405openalex-snapshot

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

inferred← citeshttps://doi.org/10.1101/2021.05.03.442258openalex-snapshot

Structures of the active HER2/HER3 receptor complex reveal dynamics at the dimerization interface induced by binding of a single ligand

inferred← citeshttps://doi.org/10.1101/2021.05.04.442654openalex-snapshot

Glioblastoma mutations impair ligand discrimination by EGFR

inferred← citeshttps://doi.org/10.1101/700906openalex-snapshot

Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator

inferred← citeshttps://doi.org/10.1101/gr.157602.113openalex-snapshot

From human genome to cancer genome: The first decade

inferred← citeshttps://doi.org/10.1101/gr.275437.121openalex-snapshot

A full-proteome, interaction-specific characterization of mutational hotspots across human cancers

inferred← citeshttps://doi.org/10.1111/1759-7714.13419openalex-snapshot

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1111/1759-7714.13757openalex-snapshot

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1111/1759-7714.13889openalex-snapshot

Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report

inferred← citeshttps://doi.org/10.1111/cas.13182openalex-snapshot

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers

inferred← citeshttps://doi.org/10.1111/iju.14082openalex-snapshot

Predictive biomarkers for drug response in bladder cancer

inferred← citeshttps://doi.org/10.1111/jcmm.12662openalex-snapshot

Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance

inferred← citeshttps://doi.org/10.1126/scitranslmed.3006802openalex-snapshot

A Genomics-Based Classification of Human Lung Tumors

inferred← citeshttps://doi.org/10.1136/esmoopen-2017-000279openalex-snapshot

Activating HER2 mutations as emerging targets in multiple solid cancers

inferred← citeshttps://doi.org/10.1136/gutjnl-2018-316039openalex-snapshot

Genomic ERBB2 / ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis

inferred← citeshttps://doi.org/10.1136/gutjnl-2018-316522openalex-snapshot

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer

inferred← citeshttps://doi.org/10.1136/jclinpath-2015-203403openalex-snapshot

Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases

inferred← citeshttps://doi.org/10.1155/2018/6242173openalex-snapshot

Characteristic of HPV Integration in the Genome and Transcriptome of Cervical Cancer Tissues

inferred← citeshttps://doi.org/10.1155/2020/6375956openalex-snapshot

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer

inferred← citeshttps://doi.org/10.1158/0008-5472.can-21-0940openalex-snapshot

Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects

inferred← citeshttps://doi.org/10.1158/0008-5472.can-22-0059openalex-snapshot

Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities

inferred← citeshttps://doi.org/10.1158/0008-5472.can-22-3617openalex-snapshot

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.22451966.v1openalex-snapshot

Supplementary Figures 1 - 8, Table 1 from Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-13-1031openalex-snapshot

A Neu View of Invasive Lobular Breast Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-13-1992openalex-snapshot

A High Frequency of Activating Extracellular Domain ERBB2 ( HER2 ) Mutation in Micropapillary Urothelial Carcinoma

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-13-2421openalex-snapshot

Positron Emission Tomography Imaging with 18F-Labeled Z HER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-14-1101openalex-snapshot

Genomic Landscape of Human Papillomavirus–Associated Cancers

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-15-3036openalex-snapshot

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-17-0900openalex-snapshot

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-17-1875openalex-snapshot

Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-18-0991openalex-snapshot

High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-18-1544openalex-snapshot

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-3205openalex-snapshot

Unbiased Detection of Driver Mutations in Extramammary Paget Disease

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-21-0885openalex-snapshot

Natural History and Characteristics of ERBB2 -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-23-2580openalex-snapshot

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room

inferred← citeshttps://doi.org/10.1158/2159-8290.22540966.v1openalex-snapshot

Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-12-0349openalex-snapshot

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-12-0585openalex-snapshot

Activating Mutations in HER2: Neu Opportunities and Neu Challenges

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-14-1211openalex-snapshot

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-15-0730openalex-snapshot

ERBB2 Emerges as a New Target for Colorectal Cancer

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-16-1431openalex-snapshot

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-18-0349openalex-snapshot

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-19-1014openalex-snapshot

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

inferred← citeshttps://doi.org/10.1158/2159-8290.cd-25-0605openalex-snapshot

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

inferred← citeshttps://doi.org/10.1158/2767-9764.crc-21-0021openalex-snapshot

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations

inferred← citeshttps://doi.org/10.1159/000502214openalex-snapshot

Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC

inferred← citeshttps://doi.org/10.1172/jci72763openalex-snapshot

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

inferred← citeshttps://doi.org/10.1177/1758835918778297openalex-snapshot

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer

inferred← citeshttps://doi.org/10.1177/2058739219827166openalex-snapshot

RETRACTED: De Novo HER2 S310Y mutation associates with poor response to EGFR tyrosine kinase inhibitor in activating EGFR-mutant NSCLC patient: A case report

inferred← citeshttps://doi.org/10.1186/1746-6148-10-19openalex-snapshot

Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation

inferred← citeshttps://doi.org/10.1186/s12885-020-07432-wopenalex-snapshot

Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions

inferred← citeshttps://doi.org/10.1186/s12885-025-14599-7openalex-snapshot

Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors

inferred← citeshttps://doi.org/10.1186/s12885-026-17058-zopenalex-snapshot

Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma

inferred← citeshttps://doi.org/10.1186/s13045-019-0725-6openalex-snapshot

Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

inferred← citeshttps://doi.org/10.1186/s13058-018-0933-yopenalex-snapshot

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors

inferred← citeshttps://doi.org/10.1186/s13073-017-0484-3openalex-snapshot

Actionable gene-based classification toward precision medicine in gastric cancer

inferred← citeshttps://doi.org/10.1186/s13073-021-00926-7openalex-snapshot

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

inferred← citeshttps://doi.org/10.1186/s40364-022-00416-xopenalex-snapshot

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives

inferred← citeshttps://doi.org/10.1200/edbk_280463openalex-snapshot

Genomic Alteration in Metastatic Breast Cancer and Its Treatment

inferred← citeshttps://doi.org/10.1200/jco.2013.49.0599openalex-snapshot

Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy

inferred← citeshttps://doi.org/10.1200/jco.2018.77.9777openalex-snapshot

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

inferred← citeshttps://doi.org/10.1200/po.16.00037openalex-snapshot

Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2–Targeted Therapy

inferred← citeshttps://doi.org/10.1200/po.22.00093openalex-snapshot

Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma

showing the first 200 of 281

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.